Postpartum depression (PPD) remains a significant global health concern, affecting approximately one in seven mothers, with profound consequences for maternal well-being, infant development, and family stability. Current therapeutic approaches, predominantly antidepressant medications and psychotherapy, have demonstrated only partial efficacy and often face challenges related to delayed onset of action, limited accessibility, and patient reluctance due to safety concerns during breastfeeding. These limitations underscore the urgent need for novel, mechanistically targeted interventions that extend beyond conventional antidepressant paradigms. Recent advances in neuroscience, endocrinology, and molecular biology have revealed complex biochemical pathways implicated in the onset and progression of PPD, offering promising avenues for next-generation therapies. Dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis, altered neuroinflammatory responses, disruptions in neurosteroid signaling, and imbalances in gut–brain axis communication are increasingly recognized as key contributors to postpartum mood disturbances. Innovative therapeutic strategies targeting these pathways, such as the modulation of allopregnanolone and related neurosteroids, anti-inflammatory agents, gut microbiome interventions, and hormonal regulation therapies, have demonstrated potential in preclinical and early clinical studies. Moreover, precision medicine approaches integrating biomarker identification and genetic profiling hold promise for tailoring interventions to individual patient profiles, enhancing treatment efficacy while minimizing adverse effects. This paradigm shift from symptom management to biochemical pathway modulation signals the emergence of a new era in PPD treatment. By harnessing cross-disciplinary insights from psychiatry, immunology, endocrinology, and systems biology, future therapies can more effectively address the multifactorial nature of postpartum depression. Such advancements not only promise improved maternal mental health outcomes but also safeguard child development and strengthen family resilience. Ultimately, exploring these biochemical underpinnings offers a transformative path toward developing safe, rapid, and sustainable next-generation interventions for postpartum depression. Bridging these scientific advances with scalable, real-world clinical applications will be critical to ensuring equitable access and meaningful outcomes for mothers worldwide.